Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Vaccination induced a highly significant (p<0.001) difference in antibodies, with 95% of participants in the NY-ESO-1/ISCOMATRIX group demonstrating antibody responses by day 71 vs 7% in the control group ( figure 3 and online supplementary table S4 ).

also in 132,142 other papers

Although the analysis was constrained by the small numbers from whom tissue was available post-relapse, there was a clear trend showing reduced double-positive cells in vaccine recipients compared with controls.

also in 19,460 other papers